Deacon S P, Karunanayake A, Barnett D
Br Med J. 1977 Nov 12;2(6097):1255-7. doi: 10.1136/bmj.2.6097.1255.
In a double-blind crossover study the symptomatic and metabolic effects of propranolol, acebutolol, and atenolol were studied during insulin-induced hypoglycaemia in diabetics treated with diet or hypoglycaemic tablets. All the drugs prevented tachycardia, but did not affect the other symptoms of hypoglycaemia. Propranolol delayed the recovery of the blood glucose concentration and impaired the secondary rise in the concentrations of blood lactate and non-esterified fatty acids in diet-treated diabetics. Acebutolol potentiated the hypoglycaemic effect of insulin in tablet-treated diabetics (mean difference of blood glucose concentration 0.7 mmol/l (12.6 mg/100 ml)) and this difference was maintained during the recovery phase4 the blood lactate response was also impaired. Atenolol did not differ perceptibly from placebo in its effect on the metabolic responses to acute hypoglycaemia. The results may be explained by differences in the known pharmacological actions of these drugs. They support the hypothesis that beta-adrenoreceptor blocking drugs that are highly beta1 specific and without membrane-stabilising activity should be safer than the non-selective drugs when used in diabetic patients at risk from hypoglycaemia.
在一项双盲交叉研究中,对饮食控制或服用降糖片的糖尿病患者在胰岛素诱导的低血糖期间,研究了普萘洛尔、醋丁洛尔和阿替洛尔的症状性和代谢性影响。所有药物均能预防心动过速,但不影响低血糖的其他症状。普萘洛尔延迟了饮食控制的糖尿病患者血糖浓度的恢复,并损害了血乳酸和非酯化脂肪酸浓度的继发性升高。醋丁洛尔增强了服用降糖片的糖尿病患者胰岛素的降糖作用(血糖浓度平均差异为0.7 mmol/L(12.6 mg/100 ml)),且在恢复阶段这种差异持续存在;血乳酸反应也受到损害。阿替洛尔对急性低血糖代谢反应的影响与安慰剂无明显差异。这些结果可用这些药物已知药理作用的差异来解释。它们支持这样的假说,即当用于有低血糖风险的糖尿病患者时,高度β1特异性且无膜稳定活性的β肾上腺素受体阻断药应比非选择性药物更安全。